Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy

por Vázquez, Ramiro, Riveiro, Maria E., Berenguer-Daizé, Caroline, O’Kane, Anthony, Gormley, Julie, Touzelet, Olivier, Rezai, Keyvan, Bekradda, Mohamed, Ouafik, L’Houcine
Publicado 2021

Role of the Tyrosine Phosphatase SHP-2 in Mediating Adrenomedullin Proangiogenic Activity in Solid Tumors

por Sigaud, Romain, Dussault, Nadège, Berenguer-Daizé, Caroline, Vellutini, Christine, Benyahia, Zohra, Cayol, Mylène, Parat, Fabrice, Mabrouk, Kamel, Vázquez, Ramiro, Riveiro, Maria E., Metellus, Philippe, Ouafik, L’Houcine
Publicado 2021

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells

por Coudé, Marie-Magdelaine, Braun, Thorsten, Berrou, Jeannig, Dupont, Mélanie, Bertrand, Sibyl, Masse, Aline, Raffoux, Emmanuel, Itzykson, Raphaël, Delord, Marc, Riveiro, Maria E., Herait, Patrice, Baruchel, André, Dombret, Hervé, Gardin, Claude
Publicado 2015

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

por Vázquez, Ramiro, Riveiro, María E, Astorgues-Xerri, Lucile, Odore, Elodie, Rezai, Keyvan, Erba, Eugenio, Panini, Nicolò, Rinaldi, Andrea, Kwee, Ivo, Beltrame, Luca, Bekradda, Mohamed, Cvitkovic, Esteban, Bertoni, Francesco, Frapolli, Roberta, D'Incalci, Maurizio
Publicado 2016

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

por Riveiro, Maria E., Astorgues-Xerri, Lucile, Vazquez, Ramiro, Frapolli, Roberta, Kwee, Ivo, Rinaldi, Andrea, Odore, Elodie, Rezai, Keyvan, Bekradda, Mohamed, Inghirami, Giorgio, D'Incalci, Maurizio, Noel, Kay, Cvitkovic, Esteban, Raymond, Eric, Bertoni, Francesco
Publicado 2016

Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes

por Boi, Michela, Todaro, Maria, Vurchio, Valentina, Yang, Shao Ning, Moon, John, Kwee, Ivo, Rinaldi, Andrea, Pan, Heng, Crescenzo, Ramona, Cheng, Mangeng, Cerchietti, Leandro, Elemento, Olivier, Riveiro, Maria E., Cvitkovic, Esteban, Bertoni, Francesco, Inghirami, Giorgio
Publicado 2016

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma

por Mensah, Afua A., Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Bomben, Riccardo, Bernasconi, Elena, Zito, Domenico, Lampis, Andrea, Hahne, Jens C., Rinaldi, Andrea, Stathis, Anastasios, Zucca, Emanuele, Kwee, Ivo, Gattei, Valter, Valeri, Nicola, Riveiro, Maria E, Bertoni, Francesco
Publicado 2018

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

por Tarantelli, Chiara, Bernasconi, Elena, Gaudio, Eugenio, Cascione, Luciano, Restelli, Valentina, Arribas, Alberto Jesus, Spriano, Filippo, Rinaldi, Andrea, Mensah, Afua Adjeiwaa, Kwee, Ivo, Ponzoni, Maurilio, Zucca, Emanuele, Carrassa, Laura, Riveiro, Maria E, Rezai, Keyvan, Stathis, Anastasios, Cvitkovic, Esteban, Bertoni, Francesco
Publicado 2018